Background: Percutaneous interventions in degenerated saphenous vein bypass grafts are associated with a high risk of periprocedural distal embolization resulting in myocardial infarction. We report the in-hospital outcomes of placement of a new polytetrafluoreoethylene-covered stent in the first US experience with this device. Methods: As palt of a prospective randomized multicenter trial (BARRICADE Trial), 88 patients were included in the roll-in phase with 104 lesions in SVGs. The use of distal protection devices was left to the discretion of the operator. In-hospital technical success, complications rats, and the incidence of MACE (death, Q-wave or non-Q-wave myocardial infarc- Conclusions: These preliminary data suggest that a simple strategy of covered-stent placement for SVG lesions offer similar outcomes as bare stents combined with distal protection. A prospective trial comparing these two strategies is warranted. showed diabetics in 32%. in Stent rsstanosis in 32%, type 82 and C lesions in 49%, vessel size < 2.9 mm in 55% and with a lesion lenght of 11.9 + 0.23 mm. One patient at day 21 discontinued the medication for Skin rash and fever (3%). There were no other side effects in this cohort of pts. Follow up cholesterol and triglycerides showed no changes compared to basal levels. Angiographic restenosis was present in 23 % of lesions (1 l/ 48) with a TVR of 22.4% (11/49). Restenosis in the nova lesions was 16.2% (8/37) compared to 45.4% (5/l 1) in Stent restenosis lesions, p=O.108. Restenosis in nova lesions with rapamycin blood level > 8 ng/ml was not founded (O/10) whereas was 22.2% (6/27) when the rapamycin blood level was < 8 nglml, p= 0.309. Conclusions: In this pilot obsewational study oral rapamycin taking during one month was safe and well tolerated. High rapamycin blood level appears to be associated with lower restenosis rats.
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Oral Siroiimus for Recalcitrant InStent Restenosis
Paul S. Teirstein, Prabhtej S. Brara, Eileen Anderson, Mark A. Grise, Mehran Moussavian, John P. Reilly, Mindy R. Fsrnandez, Scripps Clinic, La Jolla, CA Background:
Sirolimus coated Stents are a promising new therapy for restenosis. At
Scripps clinic we offered oral sirolimus to a select group of "no-option" patients at especially high risk for restenosis. These patients were followed for side effects and need for repeat revascularizations.
Methods: Patients were treated with a sirolimus loading doss of 6 mg after PTCA, followed by 2 mglday for 4 weeks. A one month course of therapy was selected because in the RAVEL trial, efficacy was demonstrated using stents that delivered Sirolimus over a 4-6 week duration. Serum electrolyies, lipid profile, renal panel, and complete blood cell count were measured at 1,3. and 5 weeks after drug initiation. Results: Oral sirolimus was prescribed to 22 patients with 28 lesions at high risk for restenosis. Patient age was 57,.1 +/-10.6 years, 9(41%) were diabetics, and 20(91%) had previous brachytherapy failure. The mean number of previous restsnoses per patient was 3.5 +/-1.6. Of the 22 study patients, 11(50%) discontinued oral sirolimus early due to side effects or laboratory abnormalities. The mean treatment duration for patients that discontinued medication early was 14.5 +/-6.5 days. Hypertriglceridemia and leukopenia were the most frequent adverse events, occurring in 3 patients each. All adverse drug effects were reversible after discontinuation.
Follow up was obtained in 100% of patients at a mean of 10 +I-2 months, ranging from 6.5-12 months. Target lesion revascularization occurred in 15 of 28 lesions (54%) and 13 of 22 patients (59%). There was no difference in TLR for patients receiving a complete 30 day course of Sirolimus 8(62%) compared to patients who terminated treatment prematurely 5(38 %), p=NS. Clinically driven repeat cardiac catheterization was obtained in 15 (68%) patients; restensosis (z&I% diameter stenosis at follow-up) was present in 13(87%).
Conclusion: Oral sirolimus does not appear to provide benefit to patients with recalcitrant restenosis. Adverse drug effetis are frequent. underscoring the importance of local drug delivery to achieve high tissue concentrations without systemic adverse drug effects.
